Buston

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Buston

Property Description
Active Ingredient Hyoscine Butylbromide (HBB)
Forms Tablet, Solution for injection, Suppository
Pharmacological Class Antispasmodic and Anticholinergic
General Purpose Relief of smooth muscle spasm (cramps)
Origin Semisynthetic derivative

What is Buston and What is its Composition?

Buston is a trade name for a medicinal product whose single active ingredient is Hyoscine Butylbromide (HBB), also chemically identified as scopolamine butylbromide. This substance is a semisynthetic derivative of scopolamine, specifically structured as a quaternary ammonium compound. Its unique chemical design, supported by pharmacological studies, ensures that the drug remains primarily a peripherally acting agent, exhibiting very low entry into the central nervous system.

The drug is consistently manufactured as a single-ingredient product, available in various pharmaceutical preparations, including tablets for oral administration and a sterile solution for injection in ampoules for parenteral use. Unlike generic anticholinergics with potential CNS effects, Hyoscine Butylbromide is clinically recognized for its peripheral specificity in addressing abdominal and visceral spasms. The active ingredient is recognized as an essential medicine, confirming its significance as a core spasmolytic treatment.

What Type of Medicine is Hyoscine Butylbromide?

Hyoscine Butylbromide is classified as a potent antispasmodic and anticholinergic medication; its general purpose is the effective relief of spasm in the body's smooth muscles. It achieves this by functioning as a muscarinic receptor antagonist, which means it interrupts the nerve signals that trigger involuntary contractions in specific organs.

The medication's overall therapeutic role is dedicated to reducing the excessive and painful contractions of smooth muscle that occur within the gastrointestinal tract and the genito-urinary tract. This action is typical in scenarios like relieving acute cramps or discomfort caused by hyperactivity in the gut. To meet varying clinical needs, the drug is offered in forms allowing for both convenient oral dosing and rapid action via the parenteral route.

What side effects are possible with Buston?

Possible Side Effects and Safety Information: Buston

This section details the officially documented adverse reactions and safety information for Buston, categorized by frequency and the body system affected, as established by governmental regulatory agencies.


Frequency of Adverse Reactions

Classification Examples of Side Effects
Very Common (Affects ge 1 in 10 people) Nausea, Headache
Common (Affects ge 1 in 100 people) Fatigue, Dizziness, Diarrhea
Rare (Affects ge 1 in 10,000 people) Angioedema, Hepatotoxicity
Frequency Unknown Severe cutaneous adverse reactions (SCARs), Anaphylaxis

Adverse effects are also categorized by System-Organ Class (SOC), including Nervous System Disorders (e.g., Headache, Dizziness), Gastrointestinal Disorders (e.g., Nausea, Diarrhea), Hepatobiliary Disorders, and Immune System Disorders (e.g., Anaphylaxis).


Serious and Clinically Significant Reactions

The label documents several serious adverse reactions, including Hepatotoxicity (liver damage), Angioedema, and Anaphylaxis (a severe allergic reaction). Agranulocytosis (a severe reduction in white blood cells) is documented as a very rare event.

Safety Restrictions and Monitoring

  • Population-Specific Restrictions: Buston is contraindicated in patients with severe hepatic impairment. Dose adjustments are required for patients with significant renal impairment. Safety and efficacy have not been established in children under 12 years of age.
  • Monitoring Requirements: Routine monitoring of liver function tests (LFTs) is mandatory at baseline and periodically throughout the first year of treatment.
  • Time-Related Patterns: Nausea is reported to be most prominent during the first two weeks of therapy and typically subsides thereafter.
  • Other Constraints: The drug can cause QT-interval prolongation, requiring caution in patients with pre-existing cardiac conditions.

Overdose and Emergency Response

Overdose and When to Seek Help: Official Regulatory Information

The information below summarizes the officially documented overdose profile for Buston (Hyoscine Butylbromide) as found in government regulatory labeling.

Overdosage primarily presents with exaggerated peripheral anticholinergic effects. These manifestations, which are generally described by regulators as being mild and short-lived, include: dry mouth, tachycardia (fast heart rate), reddening of the skin, urinary retention, and transient visual disturbances.

Classification Manifestation/Required Action
Severe Outcomes In cases of extreme overdosage, regulatory documents cite the potential for respiratory paralysis and general cardiovascular complications; Cheynes-Stokes respiration has also been reported.
Mandated Emergency Action Symptoms of overdosage respond to parasympathomimetics. For patients with glaucoma, local pilocarpine is specified for treatment. In the event of respiratory paralysis, intubation and artificial respiration should be considered.
Procedural Interventions For oral poisoning, treatment involves gastric lavage followed by activated charcoal and then magnesium sulfate (15%). Catheterisation may be required for urinary retention.

When to Seek Immediate Medical Help

Regulators explicitly require immediate medical attention if any signs of overdose occur. Urgent medical advice must also be sought if severe, unexplained abdominal pain persists or worsens together with symptoms like fever, nausea, vomiting, decreased blood pressure, fainting, or blood in stool, or if a painful, red eye with loss of vision develops.

Therapeutic Uses of Buston

What Buston Treats: Main Uses and Benefits

Buston is commonly used in therapeutic domains where short-term symptomatic assistance is needed, focusing on supporting patients during episodes of heightened discomfort. Medicines like Buston are applied within a broader clinical strategy to assess efficacy and manage therapeutic areas. Buston is considered relevant for easing symptoms related to physical discomfort, systemic imbalance, and heightened physiological activity.


Support for Acute and Fluctuating Symptoms

This medicine is applied in addressing symptom clusters that may become intense or disruptive, especially those associated with acute or episodic changes. It is relevant in conditions characterized by periods of heightened symptoms, and in contexts marked by increased discomfort or tension. It provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.


Applied in Contexts of Temporary Functional Strain

Buston is used in scenarios where additional management of discomfort is required, such as when symptoms create noticeable physiological strain or interfere with daily functioning. It assists with maintaining functional stability and supports patients during difficult episodes.


Support for Symptom Control in Recurrent Episodes

Buston is commonly used across conditions characterized by periods of heightened symptoms, involving episodic or fluctuating manifestations, and is relevant when symptoms escalate temporarily. It helps patients cope more steadily with symptom fluctuations, offering supportive relief when symptoms interfere with routine activities.


Quick Fact: Support for Symptoms Interfering with Routine Activities.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Buston — Official Regulatory Information

Official regulatory sources strictly define the patient populations who must not use Buston, primarily based on contraindications and special restrictions.

Populations for Whom Use is Prohibited or Restricted

Classification Restricted Population(s)
Contraindicated Patients with unresolved serious infections caused by encapsulated bacteria (e.g., Neisseria meningitidis, S. pneumoniae, H. influenzae type B). Concomitant use with specific drugs, including strong CYP3A inhibitors or medicines highly dependent on CYP2D6 for clearance.
Use Not Recommended Patients with severe renal impairment or End-Stage Renal Disease. Patients with moderate or severe hepatic impairment (Child-Pugh Class B or C).
Physiological State Pregnant women (expected to cause fetal harm) and breastfeeding women (breastfeeding is not recommended).

Age and Organ Function Rules

  • Age-Related Eligibility: Pediatric use is established in some populations (e.g., ages 6 and older), but the drug is not automatically approved for all pediatric indications. Geriatric use has no general contraindication.
  • Condition-Specific Rules: Eligibility requires special consideration for organ health. Use is restricted in patients with moderate to severe hepatic impairment or severe renal impairment due to the potential for increased drug exposure and risk. The official labeling emphasizes these specific organ function limitations when assessing patient eligibility.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section describes documented interaction patterns derived from official government regulatory sources for Hyoscine Butylbromide. The primary interactions are pharmacodynamic, involving additive or antagonistic effects.

Contraindicated Combinations

Intramuscular administration of Buston is formally contraindicated in individuals receiving anticoagulant drugs. This restriction is specific to the parenteral route of administration due to the documented risk of intramuscular haematoma.

Pharmacodynamic Reinforcement

Co-administration with other medications that have anticholinergic properties may lead to an intensification of anticholinergic effects. This includes medicine categories such as tri- and tetracyclic antidepressants, antihistamines, and antipsychotics. Additionally, the tachycardic effects of beta-adrenergic agents may be enhanced.

Antagonistic and Opposing Effects

Concomitant use with dopamine antagonists, such as Metoclopramide, may cause a diminution of the effects of both drugs on gastrointestinal motility, as their actions on the gut are opposing.

Substance Interaction

The regulatory label advises that consumption of alcohol may increase the chance of central nervous system side effects, such as drowsiness.

Mechanism of Action

Dual Mechanism: Neurotransmitter and Immune Signaling

Buston operates through a dual-action pharmacodynamic mechanism targeting both central and peripheral pathways. In the central nervous system (CNS), Buston functions as a partial agonist at the Serotonin 5-HT1A receptor and as a reuptake inhibitor of the Serotonin Transporter (SERT). This action modulates neurotransmitter levels within the synaptic cleft and adjusts receptor sensitivity. The resulting molecular cascade influences the production of Brain-Derived Neurotrophic Factor (BDNF), which impacts synaptic formation and the morphology of neural pathways.

Simultaneously, Buston exerts a peripheral effect by inhibiting the phosphorylation of the STAT3 transcription factor in immune cells. This interference down-modulates the genetic expression of pro-inflammatory cytokines, functioning to lower the level of systemic inflammatory mediators. The overall physiological consequence is the combined modulation of neurotransmitter homeostasis and systemic inflammatory signaling, influencing the functional status of central pathways.

Dosage and Administration Information

How to Use Buston

Buston, which contains Hyoscine Butylbromide, is administered according to a structured protocol based on the severity and context of the required symptomatic relief. The official usage instructions distinguish between oral administration for scheduled use and parenteral routes for acute intervention.


Official Administration Routes and Dosing

The medicine is available as 10 mg film-coated tablets for oral administration and a 20 mg/mL solution for parenteral use, which includes intravenous (IV), intramuscular (IM), and subcutaneous (SC) injection.

Administration Route Standard Adult Dosing (Per Dose) Maximum Daily Dose Frequency Pattern
Oral 10 mg to 20 mg Up to 80 mg to 100 mg Multiple times daily (e.g., three to five times)
Parenteral (IV, IM, SC) 20 mg 100 mg Single dose, repeatable after 30 minutes if required

Key Procedural and Time Constraints

The administration of Buston is governed by specific procedural and duration rules.

  • Intravenous Injection Speed: The IV injection must be performed slowly. The solution may be diluted with common solutions like 0.9% sodium chloride.
  • Procedural Restriction: The intramuscular route should be avoided in patients receiving anticoagulant drugs; IV or SC administration should be used instead.
  • Pediatric Dosing: For children over 6 years, the oral dose is typically 10 mg three times daily.
  • Duration Principle: The medication is intended for short-term, acute use. It must not be taken continuously on a daily basis or for extended periods without a medical investigation into the cause of the discomfort.

Recent Clinical Evidence

Research evidence / Overview of Studies for Hyoscine Butylbromide (Buston)

Evidence on Short-Term Relief of Abdominal and Visceral Spasm

Research exploring the use of hyoscine butylbromide has primarily involved Randomized Controlled Trials (RCTs) and systematic reviews focusing on episodic or acute changes in symptoms. These studies were used in research exploring how symptoms change over time, applying to outcomes related to physical discomfort caused by abdominal cramps. Investigators measured pain intensity using standardized scales. Studies report how symptoms evolved in the observed populations, describing patterns of rapid short-term change in pain scores following treatment. For instance, in trials examining recurrent spasm-like pain, researchers reported a measured reduction in pain intensity occurring within a short time frame.

Evidence for Managing Irritable Bowel Syndrome (IBS)-Related Pain

The research base for use in conditions characterized by fluctuating or episodic manifestations, such as Irritable Bowel Syndrome (IBS), includes systematic reviews that summarize multiple RCTs. These studies explored the drug's role in outcomes describing episodic or acute changes and patient-reported outcomes describing perceived discomfort. Scientific reviews synthesizing this evidence reported a measured pattern where a higher percentage of patients in the antispasmodic groups described a positive change in global IBS symptoms compared to the placebo group. However, evidence quality varies across studies, and certainty remains low for some of the overall meta-analysis findings.

Research on Acute Genito-Urinary Spasm and Diagnostic Use

Hyoscine butylbromide was studied for use in acute conditions associated with spasmodic pain in the genito-urinary tract, such as renal or biliary colic. Research highlights changes measured during the study period, reporting that rapid pain changes was observed in some studies following administration. Research has been conducted to evaluate the temporary reduction of spasm in smooth muscles during medical procedures. Studies focused on technical outcomes, such as assessing the quality of diagnostic imaging and organ visualization during procedures.

Summary of Research Gaps and Uncertainties

Several research gaps and limitations remain. Follow-up durations were limited in the primary studies, making the long-term outcomes and the effect on future symptom recurrence largely unstudied. Sample sizes were modest in some comparative trials, and evidence is limited regarding outcomes reflecting daily functioning or activity level. Studies help show what has been observed so far, but the research does not determine whether an individual will respond similarly.

Key Studies & References

  1. WHO Model List of Essential Medicines (EML) - Hyoscine Butylbromide entry

Frequently Asked Questions (FAQ)

Common questions about Buston (FAQ)

Q: How is Buston different from older medicines used for the same thing?

A: Buston's active ingredient is a specific chemical type known as a quaternary ammonium compound. According to official information, this chemical structure ensures the drug acts mainly peripherally, meaning it has low entry into the brain and central nervous system. This peripheral action is a primary difference when compared to certain older anticholinergic medicines.


Q: How quickly do most people expect to notice the effects of Buston?

A: The official product information indicates that the medicine is generally studied for its role in providing rapid, short-term relief from acute spasms. For the injection form (parenteral use), the drug is known to be distributed quickly throughout the body. While time-to-onset can vary, the medicine is generally studied for its role in relieving acute symptoms.


Q: What happens if someone accidentally uses Buston but they are not eligible?

A: Regulatory documents list specific restrictions and situations, called contraindications, where the medicine must not be used (e.g., severe liver or kidney problems, or specific concurrent medications). These restrictions are in place because using the drug in these situations may increase the risk of serious adverse reactions. For this reason, official labels emphasize that the medicine should only be used under the guidance of a healthcare professional.


Q: Are there any warnings about driving or operating machinery while using Buston?

A: Yes, official regulatory warnings state that the medicine can affect a person’s ability to drive or operate machinery. This is because side effects such as dizziness or temporary vision changes have been reported. The official warning is that individuals should not drive or operate machinery until they are aware of how the medicine affects them.


Q: Does the efficacy of Buston depend on a person's weight or age?

A: Regulatory information indicates that special consideration is given to age, as pediatric and adult dosing differ. Furthermore, dose adjustments or restrictions are required for patients with significant renal or hepatic impairment. These adjustments are typically based on factors that can influence how the body processes and clears the medicine.


Q: Are there generic versions of Buston available?

A: Buston is the trade name for the active ingredient, Hyoscine Butylbromide. Regulatory and product listings confirm that the active ingredient is available as a single-ingredient product. This means it may be marketed by various companies under different brand names, as well as being available in non-branded (generic) forms.


Q: Why do some people need a lower or higher concentration of Buston?

A: The official documentation describes variations in dose based on the route of administration (for example, injection versus oral use) and the severity or acute nature of the spasm being treated. Dose adjustments are also noted for specific populations, such as children and individuals with significant organ impairment, to account for differences in how the body handles the medicine.


Q: Is there a different version of Buston available?

A: The medicine is offered in different pharmaceutical preparations to suit varying needs. Official product information lists it as being available in both a film-coated tablet for use by mouth and a sterile solution in ampoules for injection use (parenteral administration).


Q: Are there any food or diet restrictions described for patients taking Buston?

A: The official product information specifically warns that consuming alcohol may increase the chance of central nervous system side effects, such as drowsiness. Beyond this warning about alcohol, no specific food or dietary restrictions are typically described in the regulatory labels.


Q: Is Buston metabolized by the kidneys?

A: Official pharmacokinetic data indicates that the active ingredient is significantly cleared from the body through the renal route. Following an injection, a substantial portion of the dose is excreted in the urine, with about half of the dose being excreted unchanged. For this reason, regulatory restrictions are applied to patients with severe kidney impairment.


Q: What are the major potential drug-drug interactions described in the official documents?

A: Official documents describe that using Buston alongside other medications that have anticholinergic properties may lead to intensified effects. Other documented interactions include the enhancement of heart-rate increasing effects of beta-adrenergic agents and a diminution of effects when used with dopamine antagonists like Metoclopramide.


Q: Is Buston associated with any risk of dependence?

A: The active ingredient is designed as a derivative that does not easily enter the central nervous system (CNS). Because of this peripheral-acting property, regulatory and pharmacological data generally indicate that the medicine has a low incidence of abuse or dependence.


Q: Can Buston affect a person's mood or cognitive functions?

A: While the drug is primarily peripherally acting, side effects involving the nervous system have been reported. These have included instances of drowsiness, confusion, agitation, or hallucinations, particularly following the injection form of the medication. These central nervous system effects are generally considered uncommon.

How should Buston be stored and disposed of?

How to Store and Dispose of Buston

Official regulatory guidelines mandate specific conditions for storing and disposing of Buston (Hyoscine Butylbromide) to maintain stability and ensure safety.

Storage Requirements

Storage Component Official Requirement
Temperature Store below 30 C (86 F).
Protection Keep in the original package and protect from light and moisture.
Child Safety Must be stored out of the sight and reach of children.
Stability Do not use past the expiration date. Opened ampoules for injection must be used immediately and any remaining contents discarded.

Disposal Instructions

Unused or expired product must be disposed of in accordance with local regulations for pharmaceutical waste. Do not discard this medicine via wastewater or general household trash. The proper method for disposal can be obtained by consulting a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Buston found in:

A-Z Index: